Key facts
- It has raised $90K; the latest was Later Stage VC in Aug 2025.
- Notable investors include Shenzhen Guozhong Venture Capital Management, Lime Capital, Shenzhen Strategic Emerging Industries Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Huanova
- ·The full record, as it builds
Funding rounds
No funding rounds for Huanova are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Huanova
Developer of regenerative biomaterials designed to advance organ and tissue repair across clinical and aesthetic applications. The company offers injectable, absorbable supramolecular hydrogels with self-healing properties, enabling surgical, dental and cosmetic practitioners to perform minimally invasive procedures with enhanced healing precision.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2017
- Employees
- 7
- Website
- huanova.com/
- Ownership
- Privately Held (backing)
Huanova doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Huanova shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Huanova in its N-PORT filings yet. We sweep new filings monthly.